<DOC>
	<DOCNO>NCT02623062</DOCNO>
	<brief_summary>This study conduct China provide evidence inclusion application competent authority Compound Sodium Alginate Oral Suspension sachet effective managing symptom heartburn acid regurgitation patient gastro-esophageal reflux disease ( GERD ) .</brief_summary>
	<brief_title>Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study</brief_title>
	<detailed_description>This multi-centre , randomise , double blind , two arm , parallel group , placebo-controlled clinical trial patient moderate severe frequent GERD symptom . After sign write informed consent , patient undergo screen period 7 day . Patients satisfy study entry requirement within 7 day consent , randomise receive either Compound Sodium Alginate Oral Suspension sachet ( 20ml four time daily ) match placebo sachet ( 20ml four time daily ) , 7- day treatment period . At begin end treatment period , patient require complete Reflux Disease Questionnaire ( RDQ ) . In addition , end 7 ( -1 day +2 day ) day treatment period , patient require complete Overall Treatment Evaluation .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Alginic acid</mesh_term>
	<criteria>Primary diagnosis : Current evidence symptomatic GERD/NERD comply Montreal definition GERD/Nonerosive Esophageal Reflux Disease ( NERD ) . GERD condition develop reflux stomach content cause troublesome symptom and/or complication . The concept NERD preserve typical reflux syndrome without esophageal injury , reflux esophagitis fall category esophageal syndrome esophageal injury . GERD status : patient recruit Investigator outpatient clinic , hospital database respond advertising . Patients must GERD history frequent episode GERDrelated symptom last 3 month , must troublesome heartburn and/or regurgitation least moderate intensity least 4 day week start screen . Patients must sufficiently literate able complete RDQ unaided . Patients history drug , solvent alcohol abuse ( weekly alcohol intake â‰¥ 140g ) . Patients suffer cardiac chest pain within last year . Patients suffer recent , significant unexplained weight loss 6 kg last 6 month . Female patient childbearing potential , duration study , either unwilling unable take adequate contraceptive precaution unwilling sexually abstinent . Pregnancy lactate mother . Patients history and/or symptom profile suggestive following : gastrointestinal ( GI ) disease ( e.g . gastric duodenal erosion polyps large 0.5 cm ) , erosive GERD ( Los Angeles [ LA ] classification grade CD ) , Barrett 's esophagus , peptic ulcer and/or ulcer complication , ZollingerEllison syndrome , gastric carcinoma , pyloric stenosis , oesophageal gastric surgery , intestinal obstruction , current pernicious anaemia , indication Hpylori eradication , hiatal hernia great 3 cm , know gastrointestinal bleeding ( hematochezia hematemesis ) within last 3 month , severe disease major body system . Patients take anticholinesterase drug , traditional Chinese medicine treat gastrointestinal disease , Ulcermin misoprostol preparation within 7 day prior screen throughout study . Patients take Proton Pump Inhibitors ( PPIs ) 10 day prior screen , prokinetics H2 antagonists 5 day prior screen , systemic glucocorticosteroids , nonsteroidal antiinflammatory drug ( NSAIDs except low dose aspirin give cardioprotection ) 3 consecutive day last 28 day prior screen PPIbased triple quadruple therapy eradication Hpylori last 28 day prior screen throughout study . Patients take antacid within 24 hour randomisation ( Visit 2 ) unwilling unable withhold take duration study . Patients take mucous membrane protection drug motility stimulant within 5 day prior screen unwilling unable withhold take duration study . Patients difficulty swallow . Patients know hypophosphataemia , phenylketonuria hypercalcaemia . Patients severe constipation , history intestinal obstruction . In opinion Investigator , patient insufficient heart kidney function patient require low sodium diet . Patients coexist condition , opinion Investigator , would likely compromise patient safety interfere assessment efficacy . Patients clinically significant abnormal laboratory value . Patients severe/impaired renal function insufficiency . Any previous history allergy know intolerance formulation constituent . Relevant clinically significant abnormality physical examination , ECG safety analysis . Previously randomise study . Employee study site . Partner firstdegree relative ( e.g . parent , sibling child ) Investigator . Participation clinical study previous 6 month . Unable opinion Investigator comply fully study requirement . Patients take require take macrolide antibiotic , erythromycin , azithromycin , day screen Patients fail screen allow reenter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>